Comparative Study of Oral Eletriptan (40mg and 80mg), Oral Sumatriptan (25mg and 50mg) and Placebo
Status:
Completed
Trial end date:
1998-01-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to compare the efficacy, toleration and safety of eletriptan
40mg and 80mg, with sumatriptan 25mg and 50mg, and placebo when given orally to subjects with
an acute migraine.
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.